Pain News and Research

Latest Pain News and Research

Medtronic initiates enrollment in Enlite Sensor study for diabetes

Medtronic, Inc. today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enlite Sensor, the company's latest innovation in continuous glucose monitoring (CGM) technology for people with diabetes.

From Medtronic 10 Nov 2011

New initiative to integrate and increase use of palliative care in ED

A new national initiative, IPAL-EM (Improving Palliative Care in Emergency Medicine) will integrate and increase the use of palliative care when seriously ill patients are admitted to the emergency department.

10 Nov 2011

Merck's NEXPLANON 68 mg now available in the U.S.

Merck today announced that NEXPLANON (etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.

10 Nov 2011

PDI third quarter revenues increase 4% to $37.2 million

PDI, Inc., today reported financial and operational results for the third quarter ended September 30, 2011.

10 Nov 2011

ACADIA third quarter revenues decrease to $584,000

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2011.

9 Nov 2011

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR or Stalevo, in patients with advanced Parkinson's disease.

9 Nov 2011

NIH announces results from first large scale study on treatment of prescription opioid addiction

People addicted to prescription painkillers reduce their opioid abuse when given sustained treatment with the medication buprenorphine plus naloxone (Suboxone), according to research published in yesterday's Archives of General Psychiatry and conducted by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

9 Nov 2011

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the American College of Rheumatology Scientific Meeting in Chicago, IL.

9 Nov 2011

Teenage girls with recurrent PID face fivefold risk of chronic pelvic pain and high rates of infertility

A study of the long-term consequences of pelvic inflammatory disease (PID) led by researchers at the Johns Hopkins Children's Center shows repeated bouts of the disease can double a woman's risk of infertility and quadruple her risk of chronic pelvic pain.

9 Nov 2011

Another tool to fight pharmacy crime through Twitter

...

9 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

QRxPharma receives FDA written acceptance for review of MoxDuo IR NDA

QRxPharma Limited announced today it received written acceptance from the United States Food and Drug Administration (FDA) for review of the MoxDuo IR New Drug Application (NDA) filed earlier this year.

9 Nov 2011

Omeros third quarter net loss decreases to $6.5 million

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2011.

9 Nov 2011

American Anesthesiology acquires Austin Anesthesiology Group

American Anesthesiology, a division of MEDNAX, Inc., today announced the acquisition of Austin Anesthesiology Group, L.L.P., a physician group practice that provides comprehensive adult and pediatric anesthesia services in Austin, TX.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

AcelRx reports revenue of $408,000 for third quarter 2011

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

DFINE closes $25 million round of equity financing

DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.

9 Nov 2011

Salix enters definitive agreement to acquire Oceana Therapeutics

Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately-held global provider of gastroenterology and urology therapeutics, for $300 million in cash.

8 Nov 2011

New breast and ovarian cancer vaccine in the pipeline: Study

A new vaccine is being tried clinically to combat tumor cells in a small study of advanced breast and ovarian cancer patients. The results show that there is improvement in overall survival times and stopping the disease for a handful of breast cancer patients.

8 Nov 2011

Stem cell therapy for Parkinson’s

U.S. researchers have finally found a way to overcome difficulties in coaxing human embryonic stem cells to become the neurons killed by Parkinson's disease.

8 Nov 2011